Ramazan Aytaç Olacak

Ramazan Aytaç Olacak

Auto-generated profile, based on publicly available information

Ramazan Aytaç Olacak


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
AAABDURRAHMAN AYKUT
ABDURRAHMAN AYKUT
KTKenan Turgutalp
Kenan Turgutalp
DSDamla Hazal Sucu
Damla Hazal Sucu
RORamazan Aytaç Olacak
Ramazan Aytaç Olacak
Aim Ankylosing Spondylitis (AS), a form of inflammatory arthritis of the spine, often presents as chronic back pain before age 45. This study examines the role of the Systemic Immune Response Index (SII) and Systemic Inflammation Response Index (SIRI) in diagnosing AS and monitoring treatment in patients receiving anti-TNF-α therapy. Methods This study included 90 participants (45 AS patients on anti-TNF therapy and 45 healthy controls). Age, gender, demographic data, inflammation markers (neutrophils, lymphocytes, platelets, ESR, CRP), and disease activity levels (using BASDAI) were retrospectively collected. SII and SIRI values were measured at baseline and after 3 and 6 months of TNF therapy. Results The SII and SIRI values of the patient group at baseline were higher than those of the healthy group (p<0.001). ROC analysis of the discrimination power of the data of AS patients who were started on anti-TNF drugs at the time of treatment initiation, on the healthy group, showed that the success of SII and SIRI values in classification was statistically significant (p<0.001). According to this model, the pre-treatment SII value of the patient group had a sensitivity of 68.9% and a specificity of 86.7%, and the SIRI value had a sensitivity of 62.2% and a specificity of 82.2%. SII and SIRI values measured at 3 and 6 months after treatment were significantly lower than baseline (p<0.001). SII and SIRI were positively correlated with CRP and ESR. Conclusion SII and SIRI may be a reliable and easily accessible biomarker for the diagnosis and follow-up of patients with AS.